ホーム>>6-(7-Nitro-benzo[2,1,3]oxadiazol-4-ylamino)-hexanoyl-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys((7-dimethylaminocoumarin-4-yl)-acetyl)-NH2

6-(7-Nitro-benzo[2,1,3]oxadiazol-4-ylamino)-hexanoyl-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys((7-dimethylaminocoumarin-4-yl)-acetyl)-NH2

カタログ番号GA20442

NBD-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys(DMC)-NH?(NBD-RPKPLA-Nva-WK(DMC)アミド)は、マトリックスメタロプロテアーゼストロメリシン(MMP-3)の加水分解に対する優れた蛍光基質です。このFRET基質は高感度を示し、低い基質回転数で精度が向上します。kcat/Km値は2.14 x 10? M?¹s?¹であり、350 nm(励起)および465 nm(発光)で容易に検出できます。したがって、この化合物は高スループットの阻害剤スクリーニングに適したツールです。

Products are for research use only. Not for human use. We do not sell to patients.

6-(7-Nitro-benzo[2,1,3]oxadiazol-4-ylamino)-hexanoyl-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys((7-dimethylaminocoumarin-4-yl)-acetyl)-NH2 化学構造

Cas No.: 945414-97-1

サイズ 価格 在庫数 個数
1mg
$629.00
在庫あり
5mg
$2,518.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NBD-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys(DMC)-NH (NBD-RPKPLA-Nva-WK(DMC) amide) is an excellent fluorogenic substrate for hydrolysis of the matrix metalloproteinase stromelysin (MMP-3). This FRET substrate exhibits high sensitivity and improves accuracy

レビュー

Review for 6-(7-Nitro-benzo[2,1,3]oxadiazol-4-ylamino)-hexanoyl-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys((7-dimethylaminocoumarin-4-yl)-acetyl)-NH2

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 6-(7-Nitro-benzo[2,1,3]oxadiazol-4-ylamino)-hexanoyl-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys((7-dimethylaminocoumarin-4-yl)-acetyl)-NH2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.